Gold Fields Limited (GFI) Stock Price Today
Aura AI Summary
Key Stats
- $40.79BMarket Cap
- -Volume
- Basic MaterialsSector
- $61.5252W High
- $31.2552W Low
- -Typical Hold Time
- $41.39BEnterprise Value
- 5%Div Yield
- -Trading Activity
Track Gold Fields Limited (GFI) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gold Fields Limited has traded between a low of $31.25 and a high of $61.52, highlighting its annual price range. Buy and sell Gold Fields Limited shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Most Recent News
Nutex Health hit by ransomware; patient and employee data stolen and threatened for release
Nutex Health, a micro-hospital operator, suffered a ransomware attack by The Gentlemen group, which accessed and stole confidential patient, employee, and business data. The attackers threatened to publish the stolen information, increasing risks of ...
Oil prices rise over 2% amid escalating US-Iran tensions and attacks in the Middle East
Oil prices surged as tensions in the Middle East escalated following recent US strikes on Iran and retaliatory attacks by Iran on US allies Kuwait, Jordan, and Bahrain. Brent crude futures rose over 2% to $96.59 a barrel, while US West Texas Intermed...
Alumis stock plunges 57% after lupus drug trial fails, but psoriasis drug progress continues.
Alumis' stock dropped 56.58% after its Phase II lupus drug trial failed to meet main goals, causing a significant market reaction. However, positive results in a subgroup of lupus patients with a high interferon gene signature offer a potential path ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.